Kiora Pharmaceuticals, Inc. Common Stock(KPRX)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.0B
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of …
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +0.87% | 5 |
| Feb | -7.87% | 5 |
| Mar | -6.91% | 5 |
| Apr | +3.51% | 5 |
| May | -12.88% | 5 |
| Jun | -14.96% | 5 |
| Jul | -16.89% | 4 |
| Aug | +0.01% | 4 |
| Sep | -0.87% | 4 |
| Oct | -3.66% | 4 |
| Nov | -20.59% | 5 |
| Dec | -0.21% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 1.41
- Correlation (SPY)
- 27.9%
- R²
- 0.08
- Ann. Volatility
- 62.7%
- SPY Volatility
- 12.3%
High volatility - stock moves more than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-04-02 | Eric Joseph Daniels | Chief Development Officer | Tax (F) | −929 | $1.95 | -$1.8K | EDGAR |
| 2026-04-02 | Brian M. Strem | President and CEO | Tax (F) | −1,906 | $1.95 | -$3.7K | EDGAR |
| 2026-04-02 | Melissa Tosca | CFO | Tax (F) | −929 | $1.95 | -$1.8K | EDGAR |
| 2026-03-10 | Brian M. Strem | President and CEO | Award (A) | +16,733 | — | EDGAR | |
| 2026-03-10 | Melissa Tosca | CFO | Award (A) | +6,533 | — | EDGAR | |
| 2026-03-10 | Eric Joseph Daniels | Chief Development Officer | Award (A) | +6,533 | — | EDGAR | |
| 2026-03-06 | Brian M. Strem | President and CEO | Tax (F) | −238 | $2.02 | -$481 | EDGAR |
| 2026-03-06 | Eric Joseph Daniels | Chief Development Officer | Tax (F) | −238 | $2.02 | -$481 | EDGAR |
| 2025-04-02 | PRAVEEN TYLE | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2025-04-02 | Aron Shapiro | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2025-04-02 | Lisa Walters-Hoffert | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2025-04-02 | David Hollander | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2025-04-02 | Eric Joseph Daniels | Chief Development Officer | Award (A) | +7,772 | — | EDGAR | |
| 2025-04-02 | Carmine N. Stengone | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2025-04-02 | Brian M. Strem | President and CEO | Award (A) | +15,941 | — | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | STEPHEN FROM | Executive Chairman | 67,693 | $172.6K | $0 | 2 | 2022-01-06 |
| 2 | Brian M. Strem | President and CEO | 60,692 | $154.8K | $40.2K | 11 | 2026-04-02 |
| 3 | Eric Joseph Daniels | Chief Development Officer | 31,741 | $80.9K | $7.6K | 12 | 2026-04-02 |
| 4 | Melissa Tosca | CFO | 26,975 | $68.8K | $6.9K | 9 | 2026-04-02 |
| 5 | Sarah Romano | Chief Financial Officer | 22,746 | $58.0K | $0 | 4 | 2022-02-11 |
| 6 | Erin Parsons | Director | 5,260 | $13.4K | $25.7K | 6 | 2025-04-02 |
| 7 | PRAVEEN TYLE | Director | 5,014 | $12.8K | $19.8K | 6 | 2025-04-02 |
| 8 | Aron Shapiro | Director | 3,000 | $7.6K | $10.8K | 6 | 2025-04-02 |
| 9 | Lisa Walters-Hoffert | Director | 1,250 | $3.2K | $4.8K | 3 | 2025-04-02 |
| 10 | Carmine N. Stengone | Director | 1,250 | $3.2K | $4.6K | 4 | 2025-04-02 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.